SOPHiA GENETICS director receives new share awards

SOPHiA GENETICS SA director Jean-Michel Cossery reported receiving new equity awards as part of his compensation.

Rhea-AI Filing Summary

SOPHiA GENETICS SA director Jean-Michel Cossery reported receiving new equity awards as part of his compensation. He was granted 19,724 restricted stock units, each representing one ordinary share, and 28,818 share options with a conversion price of $5.46 per share.

Both the RSUs and options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, subject to his continued service. Following these awards, Cossery directly holds 206,212 ordinary shares and 138,449 options.

Insider Trade Summary

Grant/Award: 48,542 shares

Grant/Award 2 txns

Insider Cossery Jean-Michel

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	28,818	$5.46	$157K
Grant/Award	Ordinary Shares	19,724	$5.46	$108K

Holdings After Transaction: Share Option (Right to Buy) — 138,449 contracts (Direct); Ordinary Shares — 206,212 shares (Direct)

Footnotes (2)

1. F1. Represents a restricted stock unit ("RSU") grant. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders.
2. F2. The share options were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.

Key Figures

RSU grant: 19,724 shares Option grant: 28,818 options Option exercise price: $5.46 per share +3 more

6 metrics

RSU grant 19,724 shares Restricted stock units granted June 18, 2026

Option grant 28,818 options Share options granted June 18, 2026

Option exercise price $5.46 per share Conversion or exercise price for new options

Shares after transaction 206,212 shares Ordinary shares held following grants

Options after transaction 138,449 options Total options held following grants

Option expiration June 18, 2036 Expiration date of granted share options

Key Terms

restricted stock unit ("RSU"), share options, vesting, annual meeting of shareholders

4 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") grant. Each RSU represents a contingent right..."

share options financial

"The share options were granted on June 18, 2026 and vest 100% as of the date..."

Share options are contracts that give someone the right, but not the obligation, to buy a company’s stock at a predetermined price for a limited time—think of them like a coupon to purchase shares later at a set price. They matter to investors because when exercised they increase the number of outstanding shares (dilution), can change management incentives and company value, and represent a potential future claim on profits or equity.

vesting financial

"The RSUs were granted on June 18, 2026 and vest 100% as of the date..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of shareholders financial

"vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders..."

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did SOPHiA GENETICS (SOPH) report for Jean-Michel Cossery?

SOPHiA GENETICS disclosed that director Jean-Michel Cossery received equity-based compensation, including restricted stock units and share options. These awards increase his direct holdings of ordinary shares and options, aligning his interests with shareholders through additional long-term equity exposure.

How many SOPHiA GENETICS (SOPH) ordinary shares did the director receive?

Jean-Michel Cossery received 19,724 restricted stock units, each representing one ordinary share of SOPHiA GENETICS. These units were granted on June 18, 2026 and will convert into shares only after vesting, assuming he continues his service with the company through that date.

What share options were granted to the SOPHiA GENETICS (SOPH) director?

Cossery was granted 28,818 share options with a conversion or exercise price of $5.46 per share. These options were granted on June 18, 2026, vest 100% at the next annual shareholder meeting, and expire on June 18, 2036 if not exercised before that date.

When do the new SOPHiA GENETICS (SOPH) RSUs and options vest?

Both the 19,724 restricted stock units and the 28,818 share options vest 100% as of the date of SOPHiA GENETICS’ next scheduled annual meeting of shareholders. Vesting is contingent on Jean-Michel Cossery’s continued service to the company through that vesting date.

What are Jean-Michel Cossery’s holdings in SOPHiA GENETICS (SOPH) after these grants?

After the reported grants, Cossery directly holds 206,212 ordinary shares of SOPHiA GENETICS and 138,449 share options. These figures reflect his position following the June 18, 2026 awards, providing a clearer view of his overall equity stake in the company.

Were the SOPHiA GENETICS (SOPH) insider transactions open-market purchases or compensation grants?

The transactions represent equity compensation grants, not open-market purchases. The Form 4 identifies them as grant or award acquisitions, covering restricted stock units and share options awarded on June 18, 2026, rather than shares bought or sold on a stock exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cossery Jean-Michel

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/18/2026		A		19,724(1)	A	$5.46	206,212	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$5.46	06/18/2026		A		28,818		(2)	06/18/2036	Ordinary Shares	28,818	$5.46	138,449	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") grant. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders.

2. The share options were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Jean-Michel Cossery	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)